Epic Sciences, Inc. ("Epic"), a company focused on developing diagnostics tests to facilitate personalized medicine in cancer, announced today that it has completed a Series A Equity financing led by a prominent investor. Epic will use the proceeds to expand its operations and capabilities related to its premiere Circulating Tumor Cell ("CTC') platform and to deliver on collaborations with its existing and future Pharmaceutical partners.

 "There is a revolution taking place in cancer drug development and patient management.  We are moving from the 'one size fits few approach' of chemotherapy to personalized medicine with targeted therapies," said David Nelson, Epic's President and CEO.  "The key to achieving this dream of personalized cancer medicine is having access to real-time biopsy material from each patient that you can sample over time to help guide the right therapy to the right patient.  CTCs provide that tumor biopsy material.  This financing, combined with our Pharma partnerships and our contract from the National Cancer Institute, are important steps in positioning Epic to become the premiere player in the CTC space."

About Epic Sciences
Epic Sciences, Inc. ("Epic") is a personal cancer diagnostics company built around its premiere platform to identify and characterize rare cells including circulating tumor cells ("CTCs").  Epic intends to improve cancer management by providing easily accessible and real-time biopsy material to guide clinical trials and individual treatment selection. This will facilitate personalized medicine by enabling administration of the right drug to the right patient at the right time.  Epic is working with a number of partners to achieve these goals including Pharmaceutical companies, the National Cancer Institute and the National Institutes of Health, and major cancer centers.